"Lebanon Pharmaceuticals & Healthcare Report Q2 2016" is now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Tue Apr 12 2016

We hold a cautiously optimistic outlook for Lebanon's pharmaceutical market over the coming years. The government's focus on improving healthcare access across the country coupled with a rising disease burden and relatively high per capita spending will drive the demand of high-value prescription medicines. However, the unprecedented influx of refugees escaping war-torn Syria, emergence of Islamic State violence and political stagnation pose significant downside risks to our forecast.

Headline Expenditure Projections

Pharmaceuticals : LBP2.46trn (USD1.63bn) in 2015 to LBP2.63trn (USD1.75bn) in 2016; +6.9% in local currency and +7.1% in US dollar terms. Forecast inline with last quarter.
Healthcare: LBP5.41trn (USD3.59bn) in 2015 to LBP5.89trn (USD3.91bn) in 2016; +8.7% in local currency and +8.9% in US dollar terms. Forecast inline with last quarter.

Full Report Details at
- http://www.fastmr.com/prod/1130947_lebanon_pharmaceuticals.aspx?afid=301

Risk/Reward Index

For Q216, Lebanon's Pharmaceutical Risk/Reward Index score is calculated at 52.8 out of 100, lower than last quarter's score of 55.5. The country falls three places from last quarter's position, sitting just above Bahrain (52.0) and making it the sixth most attractive market out of 31 in our Middle East and Africa matrix. Despite increased demand for modern medicines, population growth and healthcare service improvements, we believe the market's growth will be heavily constrained by the relatively small population, large urban/rural divide and limited funding. Furthermore, the country's lack of respect for intellectual property and prevalent counterfeiting, as well as the still-considerable corruption and political instability present, all drag down Lebanon's score.

Latest Updates

In January 2016, Iran's Health Minister Hassan Hashemi met with a number of Lebanese officials including Health Minister Wael Abou Faour to discuss expanding medical cooperation between the two countries.

In December 2015, Pharmaline signed a land lease agreement with King Abdullah Economic City as part of plans to build and operate its first pharmaceutical production facility in Saudi Arabia by the end of 2016.

The European commission is to give an additional EUR43mn in humanitarian aid to Lebanon for the Syrian refugee crises, which includes funds that will allow refugees access to secondary health care in Lebanese hospitals.

Health experts have warned of an impending major cholera outbreak in Lebanon following extremely poor living condition caused by a combination of the country's garbage crises, Syrian refugee crises and the approaching cold and rainy season.

BMI Economic View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Oman Pharmaceuticals & Healthcare Report Q2 2016
- Iraq Pharmaceuticals & Healthcare Report Q2 2016
- Estonia Pharmaceuticals & Healthcare Report Q2 2016
- Latvia Pharmaceuticals & Healthcare Report Q2 2016
- Egypt Pharmaceuticals & Healthcare Report Q2 2016

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »